Atosiban for Preterm Labour
Tóm tắt
Oxytocin antagonists are synthetic analogues that have the nonapeptide structure of oxytocin. They act by competing with oxytocin for receptors in the myometrium. Animal experiments and pilot clinical studies have examined several agents and, of these, atosiban has been the object of extensive clinical trials. In a large placebo-controlled trial with >500 patients, atosiban reduced the number of premature deliveries over 7 days compared with placebo with no more adverse effects than placebo. In large multicentre studies comparing atosiban with β-adre-noceptor agonists, the efficacy of the two medications was similar for pregnancy prolongation for 48 hours and for 7 days. The adverse effects, particularly cardiovascular, were considerably more frequent in the patients receiving β-adrenoceptor agonists, who had to stop treatment significantly more often than the atosiban recipients. No fetal adverse effects were seen with atosiban and, in particular, no effect on baseline fetal heart rate, unlike with the β-adrenoceptor agonists. Neonatal outcome did not differ significantly according to the treatment. The usefulness of maintenance treatment after the initial 48 hours has not been confirmed. Thus, the effectiveness of oxytocin antagonists appears to be similar to β-adrenoceptor agonists and the former are not accompanied by measurable adverse effects. Oxytocin antagonists were designed specifically as tocolytics and have been validated by the European Drug Agency. They may be the treatment of choice for preterm labour, particularly in patients at risk of cardiovascular complications (e.g. multiple pregnancy, heart disease, etc.).
Tài liệu tham khảo
Lockwood CJ. The diagnosis of preterm labour and the prediction of preterm delivery. Clin Obstet Gynecol 1995; 38: 675–87
Slattery MM, Morrison JJ. Preterm delivery. Lancet 2002; 360: 1489–97
Lettieri L, Vintzileos AM, Rodis JF, et al. Does ‘idiopathic’ preterm labor resulting in preterm birth exist? Am J Obstet Gynecol 1993; 168: 1480–5
Yoon BH, Romero R, Moon JB, et al. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2001; 185: 1130–6
Higby K, Suiter CR. A risk-benefit assessment of therapies for premature labour. Drug Saf 1999; 21: 35–56
Tsatsaris V, Papatsonis D, Goffinet F, et al. Tocolysis with nifedipine or beta-adrenergic agonists: a meta-analysis. Obstet Gynecol 2001; 97: 840–7
Papatsonis DN, Van Geijn HP, Ader HJ, et al. Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstet Gynecol 1997; 90: 230–4
Robertson PA, Sniderman SH, Laros Jr RK, et al. Neonatal morbidity according to gestational age and birth weight from five tertiary care centers in the United States, 1983 through 1986. Am J Obstet Gynecol 1992; 166: 1629–41
Melin P. Oxytocin antagonists in preterm labour and delivery. Baillieres Clin Obstet Gynaecol 1993; 7: 577–600
Chibbar R, Miller FD, Mitchell BF. Synthesis of oxytocin in amnion, chorion, and decidua may influence the timing of human parturition. J Clin Invest 1993; 91: 185–92
Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001; 81: 629–83
Bossmar T, Akerlund M, Fantoni G, et al. Receptors for and myometrial responses to oxytocin and vasopressin in preterm and term human pregnancy: effects of the oxytocin antagonist atosiban. Am J Obstet Gynecol 1994; 171: 1634–42
Fuchs AR, Romero R, Keefe D, et al. Oxytocin secretion and human parturition: pulse frequency and duration increase during spontaneous labor in women. Am J Obstet Gynecol 1991; 165: 1515–23
Thornton S, Davison JM, Baylis PH. Plasma oxytocin during the first and second stages of spontaneous human labour. Acta Endocrinol (Copenh) 1992; 126: 425–9
Fuchs AR, Fuchs F, Husslein P, et al. Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor. Science 1982; 215: 1396–8
Melin P, Trojnar J, Johansson B, et al. Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J Endocrinol 1986; 111: 125–31
Kinsler VA, Thornton S, Ashford ML, et al. The effect of the oxytocin antagonists F314 and F792 on the in vitro contractility of human myometrium. Br J Obstet Gynaecol 1996; 103: 373–5
Jenkin G. Oxytocin and prostaglandin interactions in pregnancy and at parturition. J Reprod Fertil Suppl 1992; 45: 97–111
Goodwin TM, Valenzuela G, Silver H, et al. Treatment of preterm labor with the oxytocin antagonist atosiban. Am J Perinatal 1996; 13: 143–6
Lundin S, Akerlund M, Fagerstrom PO, et al. Pharmacokinetics in the human of a new synthetic vasopressin and oxytocin uterine antagonist. Acta Endocrinol 1986; 112: 465–72
Lundin S, Breeders A, Melin P. Pharmacokinetic properties of the tocoloytic agent [MPA1, D-Tyr(ET)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers. Clin Endocrinol 1993; 39: 369–74
Zinny M. A probe study to determine the bioavailability, dose proportionality, and safety of subcutaneous atosiban administrations compared with intravenous atosiban in normal female subjects (protocol M92-020). Raritan (NJ): R.W. Johnson Pharmaceutical Research Institute, 1995 Jul 18. Internal report no. 354869: 1
Goodwin TM, Millar L, North L, et al. The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. Am J Obstet Gynecol 1995; 173: 913–7
Valenzuela GJ, Craig J, Bernhardt MD, et al. Placental passage of the oxytocin antagonist atosiban. Am J Obstet Gynecol 1995; 172: 1304–6
Akerlund M, Kostrzewska A, Laudanski T, et al. Vasopressin effects on isolated non-pregnant myometrium and uterine arteries and their inhibition by deamino-ethyl-lysine-vasopressin and deamino-ethyl-oxytocin. Br J Obstet Gynaecol 1983; 90: 732–8
Akerlund M, Hauksson A, Lundin S, et al. Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women. Br J Obstet Gynaecol 1986; 93: 22–7
Andersen LF, Lyndrup J, Akerlund M, et al. Correlation between myometrial receptor affinity, lipophilicity and antagonistic potency of oxytocin analogues in rat. J Endocrinol 1989; 118: 187–92
Romero R, Sibai BM, Sanchez-Ramos L, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 2000; 182: 1173–83
Moutquin JM, Sherman D, Cohen H, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am J Obstet Gynecol 2000; 182: 1191–9
European Atosiban Study Group. The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor: a randomized, double-blind, controlled study. Acta Obstet Gynecol Scand 2001; 80: 413–22
French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double-blind, randomized, controlled comparison with salbutamol. Eur J Obstet Gynecol Reprod Biol 2001; 98: 177–85
Worldwide Atosiban versus Beta-agonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour: the Worldwide Atosiban versus Beta-agonists Study Group. Br J Obstet Gynaecol 2001; 108: 133–42
Valenzuela GJ, Sanchez-Ramos L, Romero R, et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban: the Atosiban PTL-098 Study Group. Am J Obstet Gynecol 2000; 182: 1184–90
Oei SG, Mol BW, de Kleine MJ, et al. Nifedipine versus ritodrine for suppression of preterm labor: a meta-analysis. Acta Obstet Gynecol Scand 1999; 78: 783–8
Ray J. Meta-analysis of nifedipine versus beta-sympathomimetic agents for tocolysis during preterm labour. J Soc Obstet Gynaecol Can 1998; 20: 259–60
Doret M, Mellier G, Gaucherand P, et al. The in vitro effect of dual combinations of ritodrine, nicardipine and atosiban on contractility of pregnant rat myometrium. Br J Obstet Gynaecol 2003; 110: 731–4
Norton ME. Teratogen update: fetal effects of indomethacin administration during pregnancy. Teratology 1997; 56: 282–92
Norton ME, Merrill J, Cooper BAB, et al. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993; 329: 1602–7
Crowther CA, Moore V. Magnesium for preventing preterm birth after threatened preterm labour. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Software, 2002: CD000940
Gordon MC, Iams JD. Magnesium sulfate. Clin Obstet Gynecol 1995; 38(4): 706–12
Higby K, Xenakis EM, Pauerstein CJ. Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety. Am J Obstet Gynecol 1993; 168(4): 1247–56
Pryde PG, Besinger RE, Gianopoulos JG, et al. Adverse and beneficial effects of tocolytic therapy. Semin Perinatol 2001; 25: 316–40